AlloSource, one of the nation's largest nonprofit tissue bank cooperatives, has announced that it has signed an agreement with Henry Schein, Inc., to distribute AlloGro demineralized bone matrix (DBM) ? the only demineralized cortical bone powder that is routinely assayed* for osteoinductive activity.
Henry Schein will distribute AlloGro DBM through its state-of-the-art distribution network that serves customers across the United States.
According to Tom Cycyota, president and chief executive officer of AlloSource, as the human allograft industry continues to grow, a need for innovative ways to meet market demand is evident.
"As the largest provider of healthcare supplies to office-based practitioners in the combined North American and European markets, the new partnership with Henry Schein is a natural fit for AlloSource," Cycyota said. "Henry Schein's preeminent position in the oral surgery and periodontal markets offers us an exceptional vehicle to expand our distribution of AlloGro DBM, ultimately allowing AlloSource to further its mission of returning high-quality products to its donor areas and providing the industry with better solutions for bone grafting."
Due to favorable handling characteristics and potentially osteoinductive properties, processed allograft putties have garnered rapid market acceptance in recent years. AlloSource's AlloGro DBM can help provide osteoinductive properties. In a study published in a peer-reviewed medical journal, the AlloSource bioassay showed a strong correlation between AlloGro DBM and new bone formation in a recognized animal model of osteoinductivity.
* All AlloGro has been tested in a bioassay validated by the direct correlation between the assay in vitro and bone formation in vivo. The rapid assay measures the ability of DBM and soluble factors derived from DBM to stimulate the growth of a human osteosarcoma cell line.
